港股异动 | 百济神州(06160)涨近4% 替雷利珠单抗获欧盟委员会批准用于治疗非小细胞肺癌
百济神州(06160)涨近4%，截至发稿，涨3.54%，报84.9港元，成交额4813.84万港元。
消息面上，百济神州宣布欧盟委员会（EC）已批准替雷利珠单抗用于三项非小细胞肺癌（NSCLC）适应症的一线及二线治疗。被批准用于上述NSCLC适应症的替雷利珠单抗商品名为TIZVENI®。公司计划将NSCLC适应症与ESCC二线治疗适应症统一合并至商品名TEVIMBRA®下，TEVIMBRA®将于今年晚些时候在首批欧盟国家上市。目前，百济神州已启动超过17项替雷利珠单抗的潜在注册性，其中，11项3期随机对照和4项2期均获得积极数据。
Reprinted from 引领外汇网，the copyright all reserved by the original author.
Disclaimer: The content above represents only the views of the author or guest. It does not represent any views or positions of FOLLOWME and does not mean that FOLLOWME agrees with its statement or description, nor does it constitute any investment advice. For all actions taken by visitors based on information provided by the FOLLOWME community, the community does not assume any form of liability unless otherwise expressly promised in writing.
FOLLOWME Trading Community Website: https://www.followme.com
Hot
No comment on record. Start new comment.